Patient P-01359
Therapy response
Stable
Tolerance
Improving
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
83%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S08
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 GI symptom burden −21% vs expected — Dietary Support Protocol NP-02
- Day 48 Tolerance state changed — Unstable → Improving
- Day 49 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 50 SC-12 recommended — Supportive Compound SC-12
- Day 51 Patient accepted — Started SC-12 in the companion
- Day 52 GI-04 recommended — GI Support Protocol GI-04
- Day 53 Patient declined — Not now
- Day 57 No meaningful change — Supportive Compound SC-12
What changed?
Trajectory began diverging from predicted response on Day 49.
Primary contributors, last 14 days
- Nutritional resilience+7
- Toxicity-7
- GI instability-2
- Inflammatory activity-2
What helped?
- Dietary Support Protocol NP-02Day 31Result: symptom burden −21%
- Supportive Compound SC-12Day 50Result: no meaningful change
- GI Support Protocol GI-04Day 52Declined by patient
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 83% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 71 and rising
- WearableSleep 4.9 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 31/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 60
- WearableHRV 24 ms, trending down
- Autonomic recovery ↓65
- WearableResting HR 85 bpm
- Wearable1,138 steps/day
- WearableShort sleep window
- Drug metabolism and exposure ↑55
- DNADPYD *2A → slower clearance
- BloodToxicity index 41
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Rapid metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 3 · butyrate capacity 31/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 32 ms
- Sleep
- 5.6 h
- Steps
- 1,271
- Resting HR
- 83 bpm
Daily log: GI score 71, nutritional resilience 37, adherence 50.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01462 | 50% | S14 | NP-02 | improved | 47 |
| P-01692 | 50% | S14 | NP-02 | improved | 49 |
| P-01872 | 50% | S14 | NP-02 | improved | 47 |
| P-01393 | 49% | S14 | GI-04 | improved | 53 |
| P-01810 | 48% | S05 | NP-02 | improved | 43 |
| P-01429 | 47% | S09 | GI-04 | improved | 45 |
| P-01775 | 47% | S14 | SC-12 | improved | 48 |
| P-01865 | 47% | S14 | NP-02 | no change | 51 |
| P-01364 | 46% | S14 | GI-04 | improved | 49 |
| P-01496 | 46% | S14 | SC-12 | improved | 46 |
| P-01813 | 46% | S01 | NP-02 | no change | 40 |
| P-01332 | 45% | S14 | NP-02 | improved | 43 |